Blueprint Medicines Corp (NASDAQ:BPMC) shares, rose in value, with the stock price up by 0.57% to the previous day’s close as strong demand from buyers drove the stock to $129.28.
Actively observing the price movement in the recent trading, the stock is buoying the session at $128.55, falling within a range of $129.23 and $129.49. The value of beta (5-year monthly) is 0.833. Referring to stock’s 52-week performance, its high was $128.78, and the low was $73.04. On the whole, BPMC has fluctuated by 1.03% over the past month.
With the market capitalization of Blueprint Medicines Corp currently standing at about $8.36 billion, investors are eagerly awaiting this quarter’s results, scheduled for on 2025-May-01.
Projections by analysts suggest varying estimates for the company’s quarterly revenue. Analysts have estimated the company’s revenue for the quarter at 720.59M, with a low estimate of 165.1M and a high estimate of 180.1M. Wall Street analysts also predicted that the company’s y-o-y revenues would reach 171.34M.
Technical indicators serve as essential tools for traders, offering insights into market sentiment and potential price movements. We see that BPMC’s technical picture suggests that short-term indicators denote the stock is a 100% Buy on average. However, medium-term indicators have put the stock in the category of 100% Buy while long-term indicators on average have been pointing out that it is a 100% Buy.
The stock’s technical analysis shows that the price of BPMC currently trading nearly 0.77% and 12.51% away from the simple moving averages for 20 and 50 days respectively. The Relative Strength Index (RSI, 14) currently indicates a reading of 76.83, while the 7-day volatility ratio is showing 0.22% which for the 30-day chart, stands at 0.24%. Furthermore, Blueprint Medicines Corp (BPMC)’s beta value is 0.94.
A comparison of Blueprint Medicines Corp (BPMC) with its peers suggests the former has fared considerably weaker in the market. BPMC showed an intraday change of 0.57% in today’s session so far, and over the past year, it grew by 48.22%%.
Data on historical trading for Blueprint Medicines Corp (NASDAQ:BPMC) indicates that the trading volumes over the past 10 days have averaged 2.45 and over the past 3 months, they’ve averaged 3.05 million. According to company’s latest data on outstanding shares, there are 64.56 million shares outstanding.
Nearly 3.71% of Blueprint Medicines Corp’s shares belong to company insiders and institutional investors own 106.61% of the company’s shares. The data on short interest also indicates that stock shorts accounted for 3.13 million shares as on 2025-06-13, resulting in a short ratio of 0.62. According to the data, the short interest in Blueprint Medicines Corp (BPMC) stood at 545.00 of shares outstanding as of 2025-06-13; the number of short shares registered in 2025-05-15 reached 5.67 million. The stock has risen by 11.14% since the beginning of the year, thereby showing the potential of a further growth. This could raise investors’ confidence to be optimistic about the BPMC stock heading into the next quarter.
